Fig. 2
From: Novel drug delivery systems of Chinese medicine for the treatment of inflammatory bowel disease
(Reprinted with permission from Ref. [92]. Copyright Ivyspring International Publisher 2016)
Orally targeted HA-siCD98/CUR-NPs against UC through synergistic effects. a The fabrication process of HA-siCD98/CUR-NPs. b Scheme illustration of HA-siCD98/CUR-NPs embedded in hydrogel (chitosan/alginate) in vivo. c Accumulation of HA-functionalized NPs embedded in hydrogel in colon at four different time points after oral administration. d The concentration of fecal Lcn-2 and e H&E-stained colon sections of mice treated with different NPs for 6 days, Healthy control (1), DSS control (2), DSS + HA-siCD98-NPs (3), DSS + HA-CUR-NPs (4) and DSS + HA-siCD98/CUR-NPs (5)